Medical marijuana in neurology.

Abstract:

:Constituents of the Cannabis plant, cannabinoids, may be of therapeutic value in neurologic diseases. The most abundant cannabinoids are Δ(9)-tetrahydrocannabinol, which possesses psychoactive properties, and cannabidiol, which has no intrinsic psychoactive effects, but exhibits neuroprotective properties in preclinical studies. A small number of high-quality clinical trials support the safety and efficacy of cannabinoids for treatment of spasticity of multiple sclerosis, pain refractory to opioids, glaucoma, nausea and vomiting. Lower level clinical evidence indicates that cannabinoids may be useful for dystonia, tics, tremors, epilepsy, migraine and weight loss. Data are also limited in regards to adverse events and safety. Common nonspecific adverse events are similar to those of other CNS 'depressants' and include weakness, mood changes and dizziness. Cannabinoids can have cardiovascular adverse events and, when smoked chronically, may affect pulmonary function. Fatalities are rare even with recreational use. There is a concern about psychological dependence, but physical dependence is less well documented. Cannabis preparations may presently offer an option for compassionate use in severe neurologic diseases, but at this point, only when standard-of-care therapy is ineffective. As more high-quality clinical data are gathered, the therapeutic application of cannabinoids will likely expand.

journal_name

Expert Rev Neurother

authors

Benbadis SR,Sanchez-Ramos J,Bozorg A,Giarratano M,Kalidas K,Katzin L,Robertson D,Vu T,Smith A,Zesiewicz T

doi

10.1586/14737175.2014.985209

subject

Has Abstract

pub_date

2014-12-01 00:00:00

pages

1453-65

issue

12

eissn

1473-7175

issn

1744-8360

journal_volume

14

pub_type

杂志文章,评审
  • Pharmacological approaches for Alzheimer's disease: neurotransmitter as drug targets.

    abstract::Alzheimer's disease (AD) is the most common CNS disorder occurring worldwide. There is neither proven effective prevention for AD nor a cure for patients with this disorder. Hence, there is an urgent need to develop safer and more efficacious drugs to help combat the tremendous increase in disease progression. The pre...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.2015.988709

    authors: Prakash A,Kalra J,Mani V,Ramasamy K,Majeed AB

    更新日期:2015-01-01 00:00:00

  • New concepts in the early and preclinical detection of Parkinson's disease: therapeutic implications.

    abstract::Parkinson's disease is a chronic neurodegenerative disorder leading to progressive motor impairment for which there is no cure. Currently, the diagnosis is made by the presence of cardinal motor features and several associated non-motor symptoms. However, at this point, the underlying neuropathological changes are alr...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.12.144

    authors: Akhtar RS,Stern MB

    更新日期:2012-12-01 00:00:00

  • Role of the cholinergic system in the pathology and treatment of schizophrenia.

    abstract::Schizophrenia is a devastating psychiatric disorder; the diagnosis probably encompasses a number of illnesses with similar clinical presentations, complicating both treatment and studies into the pathology of the disorder. The development of antipsychotic medications revolutionized treatment for the disorder. However,...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.9.1.73

    authors: Scarr E,Dean B

    更新日期:2009-01-01 00:00:00

  • Post-traumatic headache.

    abstract::Post-traumatic headache (PTH) is a very controversial disorder, particularly when it comes to chronic PTH following mild closed head injury and headache attributed to whiplash injury. Nevertheless, mild traumatic brain injury is very common in Western societies, affecting approximately 1.8 million individuals in the U...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.09.84

    authors: Obermann M,Holle D,Katsarava Z

    更新日期:2009-09-01 00:00:00

  • Depression and randomized, controlled trials: problems and solutions.

    abstract::Research into what works in depression is in trouble. All treatments appear equally effective and what happens in research trials does not seem to translate into clinical practice or, to put it another way, clinical practice is not reflected in randomized controlled trials. We run the risk of designing cosmetic trials...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.6.1.41

    authors: Hatcher S

    更新日期:2006-01-01 00:00:00

  • An update on the comorbidity of ADHD and ASD: a focus on clinical management.

    abstract::Attention deficit/hyperactivity disorder (ADHD) and autism spectrum disorder (ASD) commonly co-occur. With the DSM-5, clinicians are permitted to make an ASD diagnosis in the context of ADHD. In earlier versions of the DSM, this was not acceptable. Both ASD and ADHD are reported to have had substantial increases in pr...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1586/14737175.2016.1146591

    authors: Antshel KM,Zhang-James Y,Wagner KE,Ledesma A,Faraone SV

    更新日期:2016-01-01 00:00:00

  • Voxel-based morphometry in Alzheimer's disease.

    abstract::Recent morphometric MRI studies have investigated brain volume abnormalities associated with the diagnosis of Alzheimer's disease (AD) using voxel-based morphometry (VBM). This technique allows the assessment of gray matter volumes in subjects with AD or related conditions compared with healthy controls in an automate...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.8.11.1691

    authors: Busatto GF,Diniz BS,Zanetti MV

    更新日期:2008-11-01 00:00:00

  • Why did IL-12/IL-23 antibody therapy fail in multiple sclerosis?

    abstract::Evaluation of: Segal BM, Constantinescu CS, Raychaudhuri A et al. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a Phase II, double-blind, placebo-controlled, randomized, dose-ranging study. Lancet Neurol. 7, 796-804 (2008). ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.9.3.319

    authors: Longbrake EE,Racke MK

    更新日期:2009-03-01 00:00:00

  • Update on the treatment of vitamin B6 dependent epilepsies.

    abstract::Introduction: Vitamin B6 dependent epilepsies are a group of treatable diseases (ALDH7A1 deficiency, PNPO deficiency, PLP binding protein deficiency, hyperprolinaemia type II and hypophosphatasia and glycosylphosphatidylinositol anchor synthesis defects) responding to pyridoxine or pyridoxal-5I-phosphate. Areas covere...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/14737175.2019.1648212

    authors: Mastrangelo M,Cesario S

    更新日期:2019-11-01 00:00:00

  • Promoting productive interactions between parents and physicians in the treatment of children with attention-deficit/hyperactivity disorder.

    abstract::Attention-deficit/hyperactivity disorder (ADHD) is a common neurobehavioral condition that impairs functioning throughout childhood and adolescence. Evidence-based guidelines for the treatment of ADHD recommend recognizing ADHD as a chronic condition. The chronic care model for child health emphasizes the need for pro...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.10.151

    authors: Brinkman WB,Epstein JN

    更新日期:2011-04-01 00:00:00

  • The role of extended-release quetiapine fumarate monotherapy in the treatment of patients with major depressive disorder.

    abstract::Pharmacotherapy, psychotherapy and other nonpharmacological interventions are used in patients with major depressive disorder (MDD). However, 50% of the patients with MDD fail to achieve a response to first-line antidepressant treatment. In four of five acute monotherapy studies, once-daily extended-release quetiapine...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.2013.846520

    authors: Weisler R,McIntyre RS

    更新日期:2013-11-01 00:00:00

  • Fentanyl for breakthrough pain: a systematic review.

    abstract::The purpose of this article is to systematically review the use of fentanyl as an analgesic for breakthrough pain. This article found that the oral transmucosal fentanyl (OTFC) had a quicker onset to analgesia than oral immediate-release opioids. Intranasal fentanyl (INFS) had a quicker onset to analgesia than buccal ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.11.63

    authors: Davis MP

    更新日期:2011-08-01 00:00:00

  • Cannabinoids as potential new therapy for the treatment of gliomas.

    abstract::Gliomas constitute the most frequent and malignant primary brain tumors. Current standard therapeutic strategies (surgery, radiotherapy and chemotherapeutics, e.g., temozolomide, carmustin or carboplatin) for their treatment are only palliative and survival diagnosis is normally 6-12 months. The development of new the...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.8.1.37

    authors: Parolaro D,Massi P

    更新日期:2008-01-01 00:00:00

  • Magnetic resonance and PET studies in the early diagnosis of Alzheimer's disease.

    abstract::The demographics of aging identify an immediate need for the early diagnosis and development of dementia prevention strategies. Recent neuropathological studies have pointed to the early involvement of the hippocampus and entorhinal cortex in the progression of Alzheimer's disease in the brain. In particular, these st...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.4.5.831

    authors: Mosconi L,De Santi S,Rusinek H,Convit A,de Leon MJ

    更新日期:2004-09-01 00:00:00

  • Evaluation of malnutrition in patients with nervous system disease.

    abstract::Nutritional deficiencies are independent risk factors for adverse outcomes in patients with nervous system disease. Patients with nervous system disease can often become malnourished due to swallowing difficulties or unconsciousness. This malnourishment increases hospitalization duration; average total hospital cost; ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.2014.957184

    authors: Li F,Liu YW,Wang XF,Liu GW

    更新日期:2014-10-01 00:00:00

  • Recent genetic advances in ADHD and diagnostic and therapeutic prospects.

    abstract::Attention deficit hyperactivity disorder (ADHD) is a common behavioral disorder of a complex nature. Genetic and environmental factors are thought to be involved in precipitating the disorder. Pharmacological, animal model and recent molecular studies support the role of genes (of minor or medium effect) from dopamine...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1586/14737175.3.4.453

    authors: Hawi Z,Kirley A,Lowe N,Fitzgerald M,Gill M

    更新日期:2003-07-01 00:00:00

  • Pharmacotherapy for social anxiety disorder: a systematic review.

    abstract::Social anxiety disorder (SAD) is a prevalent, disabling disorder. We aimed to assess the effects of pharmacotherapy for SAD and to determine whether particular classes of medication are more effective and/or better tolerated than others. A systematic review and meta-analysis was conducted of all published and unpublis...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.8.2.235

    authors: Ipser JC,Kariuki CM,Stein DJ

    更新日期:2008-02-01 00:00:00

  • Sumatriptan needle-free subcutaneous (Sumavel(®) DosePro™) approved for the acute treatment of migraine, with or without aura, and cluster headaches.

    abstract::Sumatriptan subcutaneous administration is the fastest and most effective of the triptans for relief of acute migraine headache. This occurs even when the patient has already developed symptoms related to central sensitization, a key parameter in determining the effectiveness of these agents. In patients whose migrain...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.11.41

    authors: Freitag FG

    更新日期:2011-04-01 00:00:00

  • Emotional dysregulation in adult ADHD: What is the empirical evidence?

    abstract::Attention deficit/hyperactivity disorder (ADHD) is a common psychiatric disorder characterized by symptoms of inattention, hyperactivity and impulsivity. There is an ongoing discussion whether symptoms of emotional dysregulation should be added to the conceptualization of ADHD in order to describe the psychopathology ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.12.109

    authors: Retz W,Stieglitz RD,Corbisiero S,Retz-Junginger P,Rösler M

    更新日期:2012-10-01 00:00:00

  • An update on the recognition and treatment of non-convulsive status epilepticus in the intensive care unit.

    abstract:INTRODUCTION:Non-convulsive status epilepticus (NCSE) is a complex and diverse condition which is often an under-recognised entity in the intensive care unit. When NCSE is identified the optimal treatment strategy is not always clear. Areas covered: This review is based on a literature review of the key literature in t...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/14737175.2017.1369880

    authors: Kinney MO,Kaplan PW

    更新日期:2017-10-01 00:00:00

  • Effects of surgical resection and adjuvant therapy on pediatric intracranial ependymomas.

    abstract::The optimal therapy of pediatric ependymomas is controversial. The benefit of surgical resection is widely accepted, but the role of adjuvant therapy is subject to debate. Due to the relatively low survival rates of ependymoma patients, as well as the tumor's high recurrence rates, further research into the efficacy o...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.5.4.465

    authors: Krieger MD,Bowen IE

    更新日期:2005-07-01 00:00:00

  • Cladribine for multiple sclerosis: review and current status.

    abstract::In the 1990s, cladribine was developed as an adenosine deaminase-resistant nucleoside analog with selective lymphotoxic specificity in the hope that it might become useful in the treatment of some lymphoid neoplasms and autoimmune disorders. Several clinical trials demonstrated very significant effectiveness and safet...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.5.6.721

    authors: Sipe JC

    更新日期:2005-11-01 00:00:00

  • The modern role of antipsychotics for the treatment of agitation and psychosis in Alzheimer's disease.

    abstract:INTRODUCTION:Antipsychotics have long been the mainstay of treatment for agitation and psychosis in Alzheimer's disease. Despite their current use successive studies have shown that they only confer a modest benefit which must be balanced against their well-established serious side effects (extrapyramidal symptoms, str...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/14737175.2018.1476140

    authors: Creese B,Da Silva MV,Johar I,Ballard C

    更新日期:2018-06-01 00:00:00

  • Guanfacine for the treatment of attention deficit hyperactivity disorder in children and adolescents.

    abstract::Guanfacine is an α2A-adrenoreceptor agonist currently indicated for the treatment of attention deficit hyperactivity disorder (ADHD). This article reviews the chemistry, pharmacodynamics and pharmacokinetics of guanfacine, as well as the clinical trial literature on guanfacine for the treatment of ADHD in children and...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.2015.1028370

    authors: Rizzo R,Martino D

    更新日期:2015-04-01 00:00:00

  • Non-pharmacological interventions and neuroplasticity in early stage Alzheimer's disease.

    abstract::Non-pharmacological interventions have the potential to reduce cognitive decline and to improve psychosocial aspects in mild cognitive impairment and Alzheimer's dementia, and the absence of side effects makes them a favorable option also for preventive strategies. We provide an overview on recent studies involving co...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.2013.845086

    authors: Herholz SC,Herholz RS,Herholz K

    更新日期:2013-11-01 00:00:00

  • Can stress increase Alzheimer's disease risk in women?

    abstract::Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by the accumulation of β-amyloid peptides and neurofibrilllary tangles in brain, resulting in neuronal death and loss of cognitive abilities. It has been hypothesized that longstanding psychological stress can result in neural degenerat...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1586/14737175.2014.878651

    authors: Johansson L

    更新日期:2014-02-01 00:00:00

  • Interferon-beta1b in multiple sclerosis.

    abstract::In 1993, interferon (IFN)-beta(1b) for subcutaneous injection became the first US FDA-approved immunomodulatory treatment for multiple sclerosis, a chronic inflammatory disease of the CNS. In this review of IFN-beta(1b), we first present a short introduction to multiple sclerosis and currently available therapeutics. ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.7.3.227

    authors: Buttmann M,Rieckmann P

    更新日期:2007-03-01 00:00:00

  • Epilepsy in the elderly.

    abstract::Epilepsy is the most common serious neurological disorder in the elderly after stroke and dementia. It may be more important for elderly people because it is intermittent and unpredictable. There is no reliable diagnostic test and so its diagnosis and management requires clinical acumen and experience. The situation i...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.10.170

    authors: Johnston A,Smith PE

    更新日期:2010-12-01 00:00:00

  • Glucocorticoids in multiple sclerosis and experimental autoimmune encephalomyelitis.

    abstract::Glucocorticoids exert a variety of immunomodulatory activities. Since changes in glucocorticoid homeostasis impact on susceptibility to autoimmune diseases, and synthetic glucocorticoids are widely used in the treatment of multiple sclerosis, a detailed understanding of their mechanism of action is desirable. Experime...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.6.11.1657

    authors: Reichardt HM,Gold R,Lühder F

    更新日期:2006-11-01 00:00:00

  • Broad spectrum micronutrient formulas for the treatment of symptoms of depression, stress, and/or anxiety: a systematic review.

    abstract::Introduction: Vitamin and mineral nutritional supplements are becoming increasingly popular as alternative treatments for anxiety and depression, as issues such as side effects from medication, failure to respond to psychotherapy and workforce limitations pose barriers for successful treatment.Areas covered: This revi...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1080/14737175.2020.1740595

    authors: Blampied M,Bell C,Gilbert C,Rucklidge JJ

    更新日期:2020-04-01 00:00:00